Introduction

Molecular Medicine Reports

1791-2997 1791-3004

D.A. Spandidos

10.3892/mmr.2017.6445

mmr-15-06-3681

Articles

Bioinformatics analysis of gene expression alterations in microRNA-122 knockout mice with hepatocellular carcinoma

Bosheng

1 * He

Ying

2 * Shi

Weixiang

1 Gong

Shenchu

1 Chen

Xiaohong

3 Xiao

Jing

4 Gu

Jinhua

5 Ding

Wenbin

1 Wang

Yilang

1Department of Radiology, The Second Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China 2Department of Ultrasound, The Tumor Hospital of Nantong University, Nantong, Jiangsu 226361, P.R. China 3Department of Ultrasound, The Second Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China 4Department of Epidemiology and Medical Statistics, School of Public Health, Nantong University, Nantong, Jiangsu 226019, P.R. China 5Department of Pathophysiology, Nantong University Medical School, Nantong, Jiangsu 226001, P.R. China 6Department of Oncology, The Second Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China

Correspondence to: Dr Wenbin Ding, Department of Radiology, The Second Affiliated Hospital of Nantong University, 6 Hai Er Xiang Road, Nantong, Jiangsu 226001, P.R. China, E-mail: dingwenbinyh@hotmail.com Dr Yilang Wang, Department of Oncology, The Second Affiliated Hospital of Nantong University, 6 Hai Er Xiang Road, Nantong, Jiangsu 226001, P.R. China, E-mail: oncowang@163.com *

Contributed equally

062017

07042017

15 6 3681 3689 31122015 06022017

2017

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Reduced microRNA (miR)-122 expression levels are frequently observed in hepatocellular carcinoma (HCC). The present study was conducted to investigate potential targets of miR-122 and determine the underlying regulatory mechanisms of miR-122 in HCC development. The public dataset GSE31731 was utilized, consisting of 8 miR-122 knockout (KO) mice (miR-122 KO) and 8 age-matched wild-type mice (WT group). Following data preprocessing, the differentially expressed genes (DEGs) were selected, followed by enrichment analysis. A protein-protein interaction (PPI) network was established, and a module network was further extracted. Combining the DEGs with microRNA targeting databases permitted the screening of the overlapping targets of miR-122. Furthermore, previously reported genes were screened out by literature mining. Transcription factors (TFs) of the targets were subsequently investigated. DEGs between miR-122 KO and WT groups were selected, including 713 upregulated and 395 downregulated genes. Of these, upregulated genes were enriched in cell cycle-associated processes [including nucleolar and spindle associated protein 1 (NUSAP1)], the cytokine-cytokine receptor interaction pathway [including C-X-C motif chemokine receptor 4 (CXCR4) and C-C motif chemokine receptor 2 (CCR2)], and the extracellular matrix-receptor interaction pathway [including integrin subunit alpha V (ITGAV)]. In addition, multiple overlapping targets were highlighted in the PPI network, including NUSAP1, CXCR4, CCR2 and ITGAV. Notably, CXCR4 and CCR2 were linked in module C, enriched in the cytokine-cytokine receptor interaction pathway. Furthermore, upregulated sex determining region Y-box 4 (SOX4) was identified as a TF. The results of the present study may provide a theoretical basis for further studies on the mechanisms of miR-122 in the development of HCC.

hepatocellular carcinoma differential analysis microRNA-122 target bioinformatics transcription factor

Introduction

Hepatocellular carcinoma (HCC) is the fifth most common cancer and the most frequent liver cancer globally (1). The majority of HCC cases occur in cirrhotic liver, and the primary risk factors are chronic hepatitis B virus or chronic hepatitis C virus (HCV) infection, which account for almost all HCC cases (2). The incidence of HCC varies between different geographical areas; however, it is increasing globally, particularly in Asia, with 6–11 per 100,000 people with the disease (3,4). A study of HCC epidemiology in Germany indicated that, despite the availability of various advanced chemotherapies and radiotherapies, including chemoembolization with drug-eluting beads, sorafenib and selective internal radiotherapy, the overall survival rate has not improved (5). Therefore, the development of more effective therapeutic methods, including molecular targeting therapy, is necessary.

Multiple studies have been conducted to investigate the molecular mechanisms underlying HCC pathogenesis and numerous gene markers have been identified in HCC, including alpha-fetoprotein, glypican-3 (a serum and histochemical marker) and transforming growth factor-β (6–8). As small, non-coding RNAs, microRNAs (miRNAs) are important regulators of cellular function and physiology (9). Controlling miRNA expression is essential for the maintenance of the steady state of cellular machinery (10). Various microRNAs (miRNAs) have been proposed as novel biomarkers of HCC prognosis, including the chromosome 19 miRNA cluster, which is overexpressed in HCC (11). HCV-induced alteration of miRNA expression regulates inflammation, leading to liver fibrosis. In addition, miRNA (miR)-449a has been reported to serve as an inhibitor in HCV patients, acting via the downregulation of chitinase-3-like protein 1 expression, which is an inflammatory marker for chronic liver diseases with fibrosis (12). Dysregulation of other miRNAs has been detected in HCC, including upregulated miR-23a, −146a and −181a, and downregulated miR-17, −338-3p and −378 (13). Notably, miR-122 is involved in HCC pathogenesis. It is commonly downregulated in HCC and the loss of miR-122 contributes to hepatocarcinogenesis in mice (14). miR-122 has additionally been reported to induce apoptosis in human HCC cell lines via targeting the anti-apoptosis gene B-cell lymphoma-2-like 2 (15). Furthermore, miR-122 inhibits cell proliferation in HCC by targeting the Wnt/β-catenin signaling pathway (16). To further understand the modulation of miR-122 in HCC development, previous studies have investigated the consequences of miR-122 deletion. Hsu et al (17) revealed that deletion of mouse mir-122 resulted in hepatocarcinogenesis and HCC-like tumor development. Although increased expression of multiple targets of miR-122 has been detected in miR-122 knockout (KO) mice, including aldolase, fructose bisphosphate A (ALDOA), solute carrier family 7 member 1, citrate synthase and cyclin G1, the functions and pathways of the targets, and the potential associations between them at the protein level, remain to be elucidated.

In the present study, the expression profile dataset generated by Hsu et al (17), GSE31731, was reanalyzed and differentially expressed genes (DEGs) were identified between miR-122 KO mice and age-matched wild-type (WT) mice. Enrichment analysis of the identified DEGs was subsequently conducted, followed by protein-protein interaction (PPI) and module analysis. Furthermore, targets of miR-122 of these DEGs were selected by combining the results with relevant databases and literature mining, followed by transcription factor (TF) analysis. By means of these comprehensive bioinformatics analyses, the present study aimed to further elucidate the involvement of miR-122 in HCC, and identify potential regulators among its targets.

Materials and methods <sec> <title>Data resources

Gene expression of GSE31731 of HCCs, which was deposited by Hsu et al (17) in the public Gene Expression Omnibus (GEO; www.ncbi.nlm.nih.gov/geo) database, was utilized in the present study. The miR-122 KO mice (liver tumor samples) and age-matched WT mice (healthy liver samples) were contained in this dataset. There were 8 biological replicates. Two-channel microarray experiments were conducted for generation of the dataset, based on the platform GPL13912 (accession no. Agilent-028005 SurePrint G3 Mouse GE 8×60 K Microarray; Agilent Technologies, Inc., Santa Clara, CA, USA).

Data pretreatment and differential expression analysis

Raw data were preprocessed using R package in Bioconductor (version 3.4; www.bioconductor.org/packages/3.0/bioc/). Following background correction and normalization, the expression value was converted from the probe level to the gene level. Subsequently, DEGs between liver tumor samples and healthy liver samples were screened out, based on the Student's t-test in Linear Models for Microarray Analysis package (version 3.30.3; www.bioconductor.org/packages/release/bioc/html/limma.html) (18). The Benjamini-Hochberg method (19) was used to adjust the P-value. The selection criteria for significant DEGs were a false discovery rate <0.01 and a log₂ fold change >1.5.

Enrichment analysis for DEGs

The Database for Annotation, Visualization and Integrated Discovery (DAVID; david.ncifcrf.gov/home.jsp) is a common tool for gene function and pathway annotation (20–22). To examine biological functions and pathways of the identified DEGs, Gene Ontology (GO; www.geneontology.org/) (23) and Kyoto Encyclopedia of Genes and Genomes (KEGG; www.genome.jp/kegg/pathway.html) (24) pathway enrichment analyses were performed using DAVID (version 6.8). Cut-off values for significant GO and KEGG pathway terms were P<0.05 and enriched gene number ≥2.

PPI network construction

To predict potential interactions between DEGs at the protein level, the DEGs were entered into the Search Tool for the Retrieval of Interacting Genes (string-db.org/) database (25). The parameter of interplayed PPIs was set as 0.7, and a prerequisite for the network construction was that all the PPI nodes were DEGs. Finally, the PPI network was visualized by Cytoscape (version 3.4.0; cytoscape.org/) software (26).

Furthermore, module analysis was performed for the PPI network using ClusterONE (version 1.0; www.paccanarolab.org/clusterone/) (27), followed by KEGG pathway enrichment analysis. The threshold for significant module selection was P<1.0×10⁻⁶.

Analysis of miR-122 targets

Initially, targets of miR-122 in mouse were downloaded from three databases: miRecords (c1.accurascience.com/miRecords/) (28), TargetScan (www.targetscan.org/) (29) and microrna.org (www.microrna.org) (30), and only genes that appeared in at least two databases were deemed to be targets of miR-122. These predicted targets were compared with the DEGs, and the overlapping genes were screened out. Following this, TFs of the overlapped targets were predicted by the iRegulon plugin of Cytoscape (iregulon.aertslab.org), which integrates a set of TF databases including Transfac, Jaspar, Encode, Swissregulon and Homer to detect enriched TF motifs and their optimal sets of direct targets (31). Normalized Enrichment Score (NES) was the measurement index for TFs of the targets and the threshold used was NES >3. Furthermore, the Agilent Literature Search plugin (Agilent Technologies, Inc.) (32), which is complementary for protein interaction data, was used to analyze the literature mining association network. In the present study, the search terms were set as ‘targets of miR-122’, context ‘liver cancer’ and species ‘Mus’, to select the reported HCC-associated literature involving miR-122.

Results <sec> <title>DEGs between miR-122 KO and WT groups

Using predefined criteria, DEGs between miR-122 KO and WT groups were screened out, including 713 upregulated and 395 downregulated genes.

Altered functions and pathways of DEGs

Based on GO and KEGG enrichment analyses, upregulated DEGs were identified to be significantly enriched in cell cycle associated biological processes (BPs), including the cell cycle, M phase and mitotic cell cycle [for example nucleolar and spindle associated protein 1 (NUSAP1); Table I], the cytokine-cytokine receptor interaction pathway [for example C-X-C motif chemokine receptor 4 (CXCR4) and C-C motif chemokine receptor 2 (CCR2); Table II], and various cancer-associated pathways, including small cell lung cancer and pathways in cancer [for example integrin subunit alpha V (ITGAV); Table II]. The downregulated DEGs were associated with oxidation-reduction (Table I) and metabolism-associated pathways, including drug metabolism, linoleic acid metabolism and retinol metabolism (Table II).

PPI network and functional module analysis

A PPI network was established, involving 549 nodes and 2,243 interplayed protein interactions (Fig. 1). Three sub-networks [modules A (Fig. 2A), B (Fig. 2B) and C (Fig. 2C)] were extracted from the PPI network. Enrichment analysis revealed that the majority of the genes in module A were upregulated and enriched in DNA replication and cell cycle-associated pathways, whereas the majority of genes in module B were downregulated and enriched in metabolism of xenobiotics by cytochrome P450 pathway (Fig. 3). In module C, the majority of the genes were upregulated and involved with the chemokine signaling pathway and the cytokine-cytokine receptor interaction pathway (Fig. 3).

Targets of miR-122

Integrating the information from miRNA databases with identified DEGs, a total of 76 overlapping genes were selected as the targets of miR-122. Enrichment analysis indicated that these genes were significantly involved in pathways in cancer (for example ITGAV; Table II), regulation of actin cytoskeleton (for example ITGAV; Table II) and cytokine-cytokine receptor interaction (for example CXCR4 and CCR2; Table II).

Notably, 39 genes of the 76 overlapping targets were additionally the predominant nodes with high degree in the PPI network, including upregulated NUSAP1 (degree=30), CXCR4 (degree=21), CCR2 (degree=20), ITGAV (degree=17) and ALDOA (degree=14); and the downregulated acyl-CoA synthetase short-chain family member 2 (degree=10). NUSAP1 was also highlighted in module A, whereas CXCR4 and CCR2 were prominent in module C.

In total, 12 TFs targeting 62 overlapping genes were predicted, including sex determining region Y-box 4 (SOX4), heterogeneous nuclear ribonucleoprotein H3, NK2 homeobox 1, inhibitor of growth family member 4, early B-cell factor 1, sex determining region Y-box 15, nuclear receptor subfamily 3 group C member 1, zinc finger protein 263, IKAROS family zinc finger 2, paired like homeodomain 3, eukaryotic translation initiation factor 5A2 and chromobox 7. The TF-target regulatory network is presented in Fig. 4. Notably, of the TFs, SOX4 was additionally an upregulated DEG.

According to literature mining, a total of 47 genes of the 76 overlapping targets were reported to be associated with HCC, including ITGAV and CXCR4. Furthermore, significantly altered expression of these genes was detected following miR-122 KO, which suggested the involvement of miR-122 in HCC development.

Discussion

miR-122 deficiency results in chronic steatohepatitis and spontaneous HCC (14). By re-analyzing the dataset GSE31731, numerous DEGs were identified between miR-122 KO and WT groups. Of these, upregulated genes were significantly enriched in cell cycle-associated processes (for example NUSAP1), cytokine-cytokine receptor interaction pathways (for example CXCR4 and CCR2), and extracellular matrix (ECM) -receptor interactions (for example ITGAV). Various overlapping targets were highlighted in the PPI network, including NUSAP1, CXCR4, CCR2 and ITGAV. Notably, NUSAP1 was predominant in module A, which was associated with the cell cycle-associated pathway, whereas CXCR4 and CCR2 were linked in module C, enriched in the cytokine-cytokine receptor interaction pathway. Furthermore, upregulated SOX4 was identified as a TF.

Restoration of miR-122 suppressed HCC tumor cell growth, and the antitumor activity was closely associated with cell cycle arrest (33). The protein encoded by NUSAP1 is a nucleolar-spindle-associated protein that acts as a positive regulator of mitosis (34). It has been identified as a cell cycle progression gene in numerous cancer types, including prostate and lung cancer (35,36). In aggressive HCC, expression of NUSAP1 is affected by other cell cycle-associated genes, including L2DTL (37). In the present study, upregulated NUSAP1 in the miR-122 KO group was significantly enriched in cell cycle-associated BPs, and additionally served as a node in module A of the PPI network, as well as one of the overlapped targets of miR-122. However, NUSAP1 has not been previously reported to be directly involved in HCC based on the literature mining results, suggesting that this gene may be a novel target of miR-122 involved in cell cycle-associated processes in HCC progression.

Dysregulation of the cytokine-cytokine receptor interaction pathway has been detected in HCC development (38,39). Activation of various chemokines in this pathway is involved in the development of numerous cancers, including HCC (40). As a chemokine receptor, the function of CXCR4 has been extensively investigated. Increased expression of CXCR4 has previously been reported to have a close association with the progression of HCC (41). In addition, CXCR4 inhibition results in antitumor effects, including the inhibition of tumor growth and the improvement of survival in mice with HCC (42). Elevated expression of CXCR4 in the miR-122 deficiency group, combined with the target information in miRNA databases, indicated that CXCR4 may be a potential target of miR-122 in HCC. CCR2 is the chemokine receptor of C-C motif chemokine ligand 2 (CCL2). Increased expression of CCR2 has previously been observed in liver leukocytes from patients with HCC (43). CCL2 is also involved in the cytokine-cytokine receptor interaction pathway and its expression is associated with HCC progression (38). Notably, CCL2 has been identified as a target of miR-122, and restoration of miR-122 results in the suppression of CCL2 in HCC (44). The results of the present study indicated that the DEG CCR2 was upregulated in the miR-122 KO group and significantly enriched in the cytokine-cytokine receptor interaction pathway. Notably, it was additionally identified as an overlapping target based on the miRNA targeting database, and was linked to CXCR4 in module C of the PPI network. These data collectively suggested that CCR2 may be a target of miR-122, and co-regulate the cytokine-cytokine receptor interaction pathway with CXCR4 in HCC development.

ECM-receptor interaction is a common pathway that is disturbed by altered gene expressions in various cancers (45,46). The gene ITGAV encodes a protein that belongs to the integrin superfamily. It has been reported to be involved in the ECM-receptor interaction pathway. It is a part of the ECM system (47), suggesting its involvement in the ECM-receptor interaction pathway. In other cancer types, including gastric cancer, ITGAV is enriched in this pathway (48). Notably, overexpressed ITGAV is induced by the gene forkhead box Q1 (FOXQ1), a member of the forkhead TF family that influences HCC metastasis (49), suggesting the potential involvement of this gene in HCC. Upregulated ITGAV in the miR-122 KO group, combined with enrichment analysis and the overlapped prediction target, indicated that this gene may be a target of miR-122 that modulates the ECM-receptor interaction pathway in HCC progression.

The intron-lacking gene SOX4 contributes to hepatocarcinogenesis and its overexpression may be a useful prognostic marker for survival after surgical resection (50). It has been demonstrated in vitro that overexpressed SOX4 is involved in p53-mediated apoptosis in HCC (50). In addition, SOX4 overexpression has previously been reported to control the metastasis of HCC (51). Thus, SOX4 has been identified as a marker gene for HCC (52). Furthermore, SOX4 serves as a TF that regulates cell differentiation. In HCC, various targets have been experimentally validated using chromatin immunoprecipitation and small interfering RNA assays, including aldo-keto reductase family 1 member B10, coiled-coil domain containing 97, dickkopf Wnt signaling pathway inhibitor 1, FOXQ1 and microtubule associated protein 4 (51). miR-191 inhibition has previously been reported to result in the upregulation of SOX4, and increased SOX4 expression promotes cell apoptosis and suppresses tumorigenesis of HCC (53). The present study indicated that the TF SOX4 may additionally be a target of miR-122.

Despite these comprehensive bioinformatics analyses, the present study has limitations. The data was downloaded from the GEO database, and the sample size was relatively small. In addition, experimental validation of the associations between miR-122 and the predicted targets was lacking, and will be addressed in follow-up studies. Furthermore, the target expression levels following miR-122 restoration were not investigated, although this would have further confirmed the targeting associations. However, the present study has significant value as it provides novel insights into the consequences of miR-122 KO in HCC progression.

In conclusion, various crucial targets of miR-122 in HCC progression were identified, including NUSAP1, CXCR4, CCR2 and ITGAV. Cell cycle-associated processes, the cytokine-cytokine receptor interaction pathway, which may be co-regulated by CXCR4 and CCR2, and the ECM-receptor interaction pathway were altered by these targets. In addition, the target SOX4 may be a TF. The results of the present study may provide a theoretical basis for further studies on the mechanisms of miR-122 in the development of HCC.

Acknowledgements

The present study was supported by the Social Development Fund of Nantong (grant no. HS2014063), the 12th Talent Summit of Top Six Industries in Jiangsu Province (grant no. WSW080) and the Project of Enhancing Medicine with Science and Education under the 13th Five-Year Plan of Nantong [grant no. Nantong MED Sci & Edu (2016) 23].

References 1

Yang

Cai

Cao

Evodiamine inhibits STAT3 signaling by inducing phosphatase shatterproof 1 in hepatocellular carcinoma cells

Cancer Lett3282432512013

10.1016/j.canlet.2012.09.019

23032719

Borel

Konstantinova

Jansen

Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma

J Hepatol56137113832012

10.1016/j.jhep.2011.11.026

22314424

Al-Mahtab

Uddin

Fazle

Akbar SM

Epidemiology and Risk Factors of Hepatocellular Carcinoma in Asia

J Gastroenterology and Hepatology Res32014

Paranaguá-Vezozzo

Ono

Alvarado-Mora

Farias

Cunha-Silva

França

Alves

Sherman

Carrilho

Epidemiology of HCC in Brazil: Incidence and risk factors in a ten-year cohort

Ann Hepatol133863932014

24927609

Weinmann

Koch

Niederle

Schulze-Bergkamen

König

Hoppe-Lotichius

Hansen

Pitton

Düber

Otto

Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: An analysis of 1066 cases of a German HCC registry

J Clin Gastroenterol482792892014

10.1097/MCG.0b013e3182a8a793

24045276

Soresi

Magliarisi

Campagna

Leto

Bonfissuto

Riili

Carroccio

Sesti

Tripi

Montalto

Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma

Anticancer Res23174717532003

12820452

Capurro

Wanless

Sherman

Deboer

Shi

Miyoshi

Filmus

Glypican-3: A novel serum and histochemical marker for hepatocellular carcinoma

Gastroenterology12589972003

10.1016/S0016-5085(03)00689-9

12851874

Murata

Matsuzaki

Yoshida

Sekimoto

Tahashi

Mori

Uemura

Sakaida

Fujisawa

Seki

Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B

Hepatology49120312172009

10.1002/hep.22765

19263472

Beta

Venkatesan

Vasudevan

Vetrivel

Khetan

Krishnakumar

Identification and insilico analysis of retinoblastoma serum microRNA profile and gene targets towards prediction of novel serum biomarkers

Bioinform Biol Insights721342013

23400111

3547501

Kosaka

Iguchi

Ochiya

Circulating microRNA in body fluid: A new potential biomarker for cancer diagnosis and prognosis

Cancer Sci101208720922010

10.1111/j.1349-7006.2010.01650.x

20624164

Augello

Vaira

Caruso

Destro

Maggioni

Park

Montorsi

Santambrogio

Roncalli

Bosari

MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic biomarker in hepatocellular carcinoma

Liver Int327727822012

10.1111/j.1478-3231.2012.02795.x

22429613

Sarma

Tiriveedhi

Subramanian

Shenoy

Crippin

Chapman

Mohanakumar

Hepatitis C virus mediated changes in miRNA-449a modulates inflammatory biomarker YKL40 through components of the NOTCH signaling pathway

PLoS One7e508262012

10.1371/journal.pone.0050826

23226395

3511274

Zhang

Liu

Wang

Teng

Niu

Huang

Liang

Hepatitis B virus and hepatocellular carcinoma at the miRNA level

World J Gastroenterol17335333582011

10.3748/wjg.v17.i28.3353

21876625

3160541

Hsu

Wang

Kutay

Bid

Shreve

Zhang

Costinean

Bratasz

Houghton

Ghoshal

Hepatic loss of miR-122 predisposes mice to hepatobiliary cyst and hepatocellular carcinoma upon diethylnitrosamine exposure

Am J Pathol183171917302013

10.1016/j.ajpath.2013.08.004

24113455

3857547

Lin

Gong

Tseng

Wang

miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines

Biochem Biophys Res Commun3753153202008

10.1016/j.bbrc.2008.07.154

18692484

Zhu

Yang

Wang

MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/β-catenin pathway

Liver Int327527602012

10.1111/j.1478-3231.2011.02750.x

22276989

Hsu

Wang

Kota

Costinean

Kutay

Bai

La Perle

Chivukula

Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver

J Clin Invest122287128832012

10.1172/JCI63539

22820288

3408748

Smyth

Limma: Linear models for microarray data

Bioinformatics and computational biology solutions using R and BioconductorSpringer3974202005

10.1007/0-387-29362-0_23

Haynes

Benjamini-Hochberg Method

Encyclopedia of Systems BiologySpringer78782013

10.1007/978-1-4419-9863-7_1215

Dennis

JrSherman

Hosack

Yang

Gao

Lane

Lempicki

DAVID: Database for annotation, visualization and integrated discovery

Genome Biol4P32003

10.1186/gb-2003-4-5-p3

12734009

W Huang

Sherman

Lempicki

Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

Nat Protoc444572009

19131956

W Huang

Sherman

Lempicki

Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists

Nucleic Acids Res371132009

10.1093/nar/gkn923

19033363

Gene Ontology ConsortiumBlake

Dolan

Drabkin

Hill

Sitnikov

Bridges

Burgess

Buza

McCarthy

Gene Ontology annotations and resources

Nucleic Acids Res41D530D5352013

10.1093/nar/gks1050

23161678

Kanehisa

Goto

Sato

Furumichi

Tanabe

KEGG for integration and interpretation of large-scale molecular data sets

Nucleic Acids Res40D109D1142012

10.1093/nar/gkr988

22080510

Szklarczyk

Franceschini

Wyder

Forslund

Heller

Huerta-Cepas

Simonovic

Roth

Santos

Tsafou

STRING v10: Protein-protein interaction networks, integrated over the tree of life

Nucleic Acids Res43D447D4522015

10.1093/nar/gku1003

25352553

Smoot

Ono

Ruscheinski

Wang

Ideker

Cytoscape 2.8: New features for data integration and network visualization

Bioinformatics274314322011

10.1093/bioinformatics/btq675

21149340

Wan

Cui

Wang

JM-Z

Liu

Gao

The PPI network and cluster ONE analysis to explain the mechanism of bladder cancer

Eur Rev Med Pharmacol Sci176186232013

23543444

Xiao

Zuo

Cai

Kang

Gao

miRecords: An integrated resource for microRNA-target interactions

Nucleic Acids Res37D105D1102009

10.1093/nar/gkn851

18996891

Lewis

Shih

Jones-Rhoades

Bartel

Burge

Prediction of mammalian microRNA targets

Cell1157877982003

10.1016/S0092-8674(03)01018-3

14697198

Betel

Wilson

Gabow

Marks

Sander

The microRNA. org resource: Targets and expression

Nucleic Acids Res36D149D1532008

10.1093/nar/gkm995

18158296

Janky

Verfaillie

Imrichová

Van de Sande

Standaert

Christiaens

Hulselmans

Herten

Sanchez

M Naval

Potier

iRegulon: from a gene list to a gene regulatory network using large motif and track collections

PLoS Comput Biol10e10037312014

10.1371/journal.pcbi.1003731

25058159

4109854

Cline

Smoot

Cerami

Kuchinsky

Landys

Workman

Christmas

Avila-Campilo

Creech

Gross

Integration of biological networks and gene expression data using Cytoscape

Nat Protoc2236623822007

10.1038/nprot.2007.324

17947979

3685583

Liu

Shen

Liu

Luo

Chen

Qian

Expression of miR-122 mediated by adenoviral vector induces apoptosis and cell cycle arrest of cancer cells

Cancer Biol Ther95545612010

10.4161/cbt.9.7.11267

20150764

Raemaekers

Ribbeck

Beaudouin

Annaert

Van Camp

Stockmans

Smets

Bouillon

Ellenberg

Carmeliet

NuSAP, a novel microtubule-associated protein involved in mitotic spindle organization

J Cell Biol162101710292003

10.1083/jcb.200302129

12963707

2172854

Cuzick

Swanson

Fisher

Brothman

Berney

Reid

Mesher

Speights

Stankiewicz

Foster

Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: A retrospective study

Lancet Oncol122452552011

10.1016/S1470-2045(10)70295-3

21310658

3091030

Zhou

Chen

Han

Wang

Chen

Identification of featured biomarkers in different types of lung cancer with DNA microarray

Mol Biol Rep41635763632014

10.1007/s11033-014-3515-9

25001589

Pan

Chou

Liu

Peng

Liu

Hsu

Role of L2DTL, cell cycle-regulated nuclear and centrosome protein, in aggressive hepatocellular carcinoma

Cell Cycle5267626872006

10.4161/cc.5.22.3500

17106265

Wan

Huang

Zhang

Comparison of gene expression in hepatocellular carcinoma, liver development, and liver regeneration

Mol Genet Genomics2834854922010

10.1007/s00438-010-0530-y

20358383

Lin

Chuang

Amphotericin B up-regulates angiogenic genes in hepatocellular carcinoma cell lines

Eur J Clin Invest392392452009

10.1111/j.1365-2362.2008.02066.x

19260954

Huang

Geng

Chemokines and hepatocellular carcinoma

World J Gastroenterol16183218362010

10.3748/wjg.v16.i15.1832

20397259

2856822

Schimanski

Bahre

Gockel

Müller

Frerichs

Hörner

Teufel

Simiantonaki

Biesterfeld

Wehler

Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4

Br J Cancer952102172006

10.1038/sj.bjc.6603251

16819541

2360625

Chen

Ramjiawan

Reiberger

Hato

Huang

Ochiai

Kitahara

Unan

Reddy

CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice

Hepatology61159116022015

10.1002/hep.27665

25529917

4406806

Chew

Tow

Teo

Wong

Chan

Gehring

Loh

Bolze

Quek

Lee

Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients

J Hepatol523703792010

10.1016/j.jhep.2009.07.013

19720422

Bandiera

Pfeffer

Baumert

Zeisel

MiR-122-a key factor and therapeutic target in liver disease

J Hepatol624484572015

10.1016/j.jhep.2014.10.004

25308172

Navab

Strumpf

Bandarchi

Zhu

Pintilie

Ramnarine

Ibrahimov

Radulovich

Leung

Barczyk

Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer

Proc Natl Acad Sci USA10871607165

2011

10.1073/pnas.1014506108

21474781

3084093

Lee

Jang

Kim

Kwak

Park

Hwang

Lee

Jang

Park

Kim

Comparative transcriptome analysis of adipose tissues reveals that ECM-receptor interaction is involved in the depot-specific adipogenesis in cattle

PLoS One8e662672013

10.1371/journal.pone.0066267

23805208

3689780

Fukui

Shaykhiev

Agosto-Perez

Mezey

Downey

Travis

Crystal

Lung adenocarcinoma subtypes based on expression of human airway basal cell genes

Eur Respir J42133213442013

10.1183/09031936.00144012

23645403

4124529

Hou

Molecular basis of the effect of midkine on tumor growth in human gastric cancer cell BGC823

Biomedicine and pharmacotherapy624222008

10.1016/j.biopha.2008.06.006

Xia

Huang

Tian

Zhang

Chen

Shang

Nie

Forkhead box Q1 promotes hepatocellular carcinoma metastasis by transactivating ZEB2 and VersicanV1 expression

Hepatology599589732014

10.1002/hep.26735

24005989

Hur

Rhim

Jung

Kim

Bae

Jang

Yang

Kim

Wang

SOX4 overexpression regulates the p53-mediated apoptosis in hepatocellular carcinoma: Clinical implication and functional analysis in vitro

Carcinogenesis31129813072010

10.1093/carcin/bgq072

20400479

Liao

Sun

Chau

Lai

Wang

Horng

Hsiao

Tsou

Identification of SOX4 target genes using phylogenetic footprinting-based prediction from expression microarrays suggests that overexpression of SOX4 potentiates metastasis in hepatocellular carcinoma

Oncogene27557855892008

10.1038/onc.2008.168

18504433

Chang

Chen

Beezhold

Castranova

Shi

Chen

JNK1 activation predicts the prognostic outcome of the human hepatocellular carcinoma

Mol Cancer81142009

10.1186/1476-4598-8-64

19128456

2628864

Elyakim

Sitbon

Faerman

Tabak

Montia

Belanis

Dov

Marcusson

Bennett

Chajut

hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy

Cancer Res70807780872010

10.1158/0008-5472.CAN-10-1313

20924108

Figure 1.

Protein-protein interaction network of differentially expressed genes. Red represents upregulated genes and blue represents downregulated genes. Lines between two genes denote interactions between them.

Figure 2.

Module network of the protein-protein interaction network. (A) Module A, (B) module B and (C) module C networks. Red represents upregulated genes and blue represents downregulated genes. Lines between two genes denote interactions between them.

Figure 3.

Functional enrichment analysis of the genes in each module network.

Figure 4.

Targets of microRNA-122 and TFs of the targets. Squares represent targets (red, upregulated; blue, downregulated), diamonds represent TFs (red, upregulated; yellow, expression without significant difference). TF, transcription factor.

Table I.

Functions altered by differentially expressed genes.

Category	Term	Count	P-value
Upregulated
BP	GO:0007049~cell cycle	57	4.96×10⁻¹¹
	GO:0000279~M phase	34	1.64×10⁻⁰⁹
	GO:0000278~mitotic cell cycle	31	2.64×10⁻⁰⁹
	GO:0007067~mitosis	27	3.21×10⁻⁰⁹
	GO:0000280~nuclear division	27	3.21×10⁻⁰⁹
CC	GO:0005576~extracellular region	133	9.92×10⁻¹⁸
	GO:0044421~extracellular region part	74	2.00×10⁻¹³
	GO:0005578~proteinaceous extracellular matrix	35	7.33×10⁻⁰⁹
	GO:0031012~extracellular matrix	35	2.01×10⁻⁰⁸
	GO:0044420~extracellular matrix part	18	4.96×10⁻⁰⁸
MF	GO:0005509~calcium ion binding	60	1.62×10⁻⁰⁷
	GO:0008009~chemokine activity	10	4.56×10⁻⁰⁶
	GO:0008201~heparin binding	14	5.26×10⁻⁰⁶
	GO:0042379~chemokine receptor binding	10	5.74×10⁻⁰⁶
	GO:0001871~pattern binding	17	9.14×10⁻⁰⁶
Downregulated
BP	GO:0055114~oxidation-reduction	64	9.82×10⁻²⁸
	GO:0006631~fatty acid metabolic process	24	4.36×10⁻¹³
	GO:0008202~steroid metabolic process	21	1.75×10⁻¹¹
	GO:0006694~steroid biosynthetic process	15	3.73×10⁻¹¹
	GO:0006956~complement activation	10	1.37×10⁻⁰⁸
CC	GO:0005777~peroxisome	22	4.28×10⁻¹⁵
	GO:0042579~microbody	22	4.28×10⁻¹⁵
	GO:0005792~microsome	26	5.15×10⁻¹⁴
	GO:0042598~vesicular fraction	26	1.13×10⁻¹³
	GO:0005739~mitochondrion	66	7.86×10⁻¹¹
MF	GO:0009055~electron carrier activity	34	4.36×10⁻²¹
	GO:0020037~heme binding	23	9.42×10⁻¹⁴
	GO:0046906~tetrapyrrole binding	23	2.57×10⁻¹³
	GO:0005506~iron ion binding	33	3.02×10⁻¹³

The top 5 functions are presented for each category, ranked by the enrichment significance. Up, upregulated differentially expressed genes; down, downregulated differentially expressed genes; BP, biological process; CC, cellular component; MF, molecular function; GO, gene ontology; count, gene numbers enriched in a specific gene ontology term.

Table II.

Pathways altered by differentially expressed genes.

Term	Count	Genes	P-value
Upregulated
mmu04060:Cytokine-cytokine receptor interaction	27	CCL2, CXCL5, CXCR4, CXCL14, CCR2	4.82×10⁻⁰⁶
mmu04512:ECM-receptor interaction	15	COL3A1, LAMA2, ITGAV, COL1A2, LAMC1	4.87×10⁻⁰⁶
mmu04510:Focal adhesion	22	COL3A1, LAMA2, ITGAV, LAMC1	4.43×10⁻⁰⁵
mmu00480:Glutathione metabolism	10	GPX2, GSTA1, GSTA2, GSTM3, G6PDX	2.05×10⁻⁰⁴
mmu04110:Cell cycle	14	CCNB2, KMYT1, BUB1B, ESPL1, CDC20	0.001940583
mmu05222:Small cell lung cancer	11	LAMA2, COL4A1, ITGAV, LAMC2, LAMC1	0.002161153
mmu04810:Regulation of actin cytoskeleton	19	ITGAX, ITGAV, PDGFRB, PAK1, DIAP3	0.002891419
mmu04062:Chemokine signaling pathway	16	CCL2, CXCR4, CXCL16, CCR2, CX3CR1	0.006803694
mmu05200:Pathways in cancer	23	COL4A1, LAMA2, ITGAV, LAMC2, LAMC1	0.011257034
mmu00590:Arachidonic acid metabolism	9	GPX2, CBR1, CYP4F18, GPX3, GGT1 et al	0.018763259
Downregulated
mmu00982:Drug metabolism	18	CYP2C37, CYP3A16, CYP2C54, CYP2C44, ADH4	1.83×10⁻¹²
mmu00980:Metabolism of xenobiotics by cytochrome P450	17	CYP2C37, CYP3A16, CYP2C54, CYP2C44, CYP2C68	2.81×10⁻¹²
mmu00591:Linoleic acid metabolism	14	CYP2J5, CYP2C37, CYP3A16, CYP2C54, CYP2C44	4.16×10⁻¹¹
mmu00830:Retinol metabolism	16	CYP2C37, CYP3A16, CYP2C54, CYP2C44, CYP2C68	6.09×10⁻¹¹
mmu03320:PPAR signaling pathway	16	ACOX1, ACSL1, CYP4A12A, HMGCS2, SCP2	5.86×10⁻¹⁰
mmu00590:Arachidonic acid metabolism	15	CYP2J5, CYP2C37, CYP2C54, CYP2C44, CYP2J8	1.14×10⁻⁰⁸
mmu00120:Primary bile acid biosynthesis	8	CYP7B1, HSD3B7, CYP7A1, CYP8B1, SCP2	2.81×10⁻⁰⁸
mmu00071:Fatty acid metabolism	9	CYP4A12B, GCDH, ACOX1, ACSL1, ADH4	1.21×10⁻⁰⁵
mmu00140:Steroid hormone biosynthesis	9	CYP7B1, CYP3A16, HSD3B6, HSD17B2, CYP7A1	1.21×10⁻⁰⁵
mmu04610:Complement and coagulation cascades	11	MBL1, C8A, MBL2, C8B, CD55	1.40×10⁻⁰⁵

The top 10 pathways are presented, ranked by the enrichment significance. Up, upregulated differentially expressed genes; down, downregulated differentially expressed genes; count, gene numbers enriched in a specific pathway term.